University of California, Berkeley
275 articles with University of California, Berkeley
Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
Tempest Therapeutics, Inc. announced that it has entered into an exclusive license with the University of California at Berkeley for intellectual property covering a drug target that was discovered in the laboratory of Russell Vance, Ph.D., professor of molecular and cell biology at U.C. Berkeley and a Howard Hughes Medical Institute investigator.
Forbes highlights its "30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
University of California, Berkeley, Study Confirms Efficacy of Prescription Drug Reference Pricing for Lowering Drug Costs for Employers and Patients
Using ActiveRADAR’s Solution, Study Featured in JAMA Builds on Previous Research to Demonstrate Power of Reference Pricing to Decrease Prescription Drug Costs over Two and a Half- and Five-Year Time Frames
Data from digital inhalers reveals an increased use of rescue inhalers for asthma symptoms due to short-term exposure to ozone, even below the ozone level set by the EPA
GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia
GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine, a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease.
Weill Neurohub Will Promote Cross-Institutional Collaboration in Brain Trauma and Neurodegenerati...
11/13/2019The Weill Family Foundation, University of California, Berkeley, University of California, San Francisco and the University of Washington launched the Weill Neurohub with a $106 million gift.
Industrial Partnership between NTT Research and the Simons Institute for the Theory of Computing Provides Framework for Collaboration
With its 16th U.S. patent, UC now holds largest U.S. CRISPR-Cas9 patent portfolio
New patent is fourth added to university's portfolio for the pioneering gene-editing technology this month
UC's U.S. CRISPR-Cas9 portfolio is most comprehensive for the gene-editing technology
Second patent received this month related to sgRNAs for the groundbreaking gene-editing technology
University's 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future
University continues momentum with sixth patent issued recently, 11th U.S. patent, expanding range of intellectual property related to the gene-editing technology
USPTO continues to award U.S. CRISPR-Cas9 patents to UC with four issued this month; eight this year; 10 overall; 15 by end of summer
University of California granted U.S. CRISPR-Cas9 patent related to production of genetically modified cells
Eighth patent in UC's wide-ranging CRISPR-Cas9 portfolio involves introducing Cas9 into a cell for genome editing
UC's growing portfolio now includes patent for genome editing in a cell using CRISPR protein-RNA complex [02-July-2019] BERKELEY, Calif. , July 2, 2019 /PRNewswire/ -- The U.S. Patent and Trademark Office has issued a new patent to the University of California (UC) covering methods of cleaving, modifying, or targeting and binding a target DNA in a cell using a CRISP
The researchers, in analyzing more than 400,000 genomes and associated health records, found that individuals with two mutated copies of the CCR5 gene, the one He Jiankui modified, had a significantly higher death rate between the ages 41 and 78 than people with one or no copies.
USPTO issues sixth CRISPR-Cas9-related patent to University of California for genome editing and modulation of gene expression
Dr. John Inglis and Dr. Richard Sever, founders of bioRxiv from Cold Spring Harbor Laboratory (CSHL), and Dr. Michael Eisen, co-founder of Public Library of Science from University of California Berkeley propose Plan Universal (Plan U) to enlist funding organizations in making research more readily available through preprint servers.
University of California Granted New CRISPR-Cas9 U.S. Patent, Further Expanding Patent Portfolio for Genome Editing
New U.S. patent, involved in prior terminated interference proceeding, is fourth patent issued to UC covering CRISPR-Cas9 gene editing